The 2023 American Association of Clinical Endocrinology (AACE) position statement on GLP-1 therapy notes that FDA-approved agents should be the first-line choice when available, citing the quality controls embedded in the approval process [10]
Extracted data included trial identifiers (NCT number, phase, duration), baseline population characteristics (baseline BMI, diabetes status), specific intervention arms and dosages, primary and secondary metabolic outcomes, and safety parameters
As a result, it assists the body in reducing appetite and improving metabolic efficiency
Its job is to help control blood sugar and signal fullness
Critically, endogenous GHRH is required for most of the GH response to GHRP-6
Females are affected more often than males (2:1)